Transitional cell carcinoma cystoscopy and bladder biopsy: Difference between revisions

	Transitional cell carcinoma Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Transitional cell carcinoma from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Staging
History and Symptoms
Physical Examination
Laboratory Findings
Cystoscopy and Bladder Biopsy
CT
MRI
Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Transitional cell carcinoma cystoscopy and bladder biopsy On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Transitional cell carcinoma cystoscopy and bladder biopsy All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Transitional cell carcinoma cystoscopy and bladder biopsy
CDC on Transitional cell carcinoma cystoscopy and bladder biopsy
Transitional cell carcinoma cystoscopy and bladder biopsy in the news
Blogs on Transitional cell carcinoma cystoscopy and bladder biopsy
Directions to Hospitals Treating Transitional cell carcinoma
Risk calculators and risk factors for Transitional cell carcinoma cystoscopy and bladder biopsy

Latest revision as of 18:34, 4 October 2019

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];Associate Editor(s)-in-Chief: Suveenkrishna Pothuru, M.B,B.S. [2]

Cystoscopy may be helpful in the diagnosis of transitional cell carcinoma.

Cystoscopy may be helpful in the diagnosis of transitional cell carcinoma.
Cystoscopy may be performed to do biopsy
Cystoscopy is the gold standard for surveillance in patients with a history of bladder cancer
To view histopathologic characteristic features of all transitional cell carcinoma, click here

@@ Line 6: / Line 6: @@
 ==Cystoscopy and Biopsy==
-* If the initial TURBT identifies muscle invasive (T2) disease, definitive therapy is generally indicated.
-* Cystectomy may also play a role in the management of patients with non-muscle invasive bladder cancer.
-* Any of the following represents a strong indication to proceed to cystectomy:
-* T1 tumors with lymphovascular invasion
-* Variant histologies, including micropapillary transitional cell carcinoma, sarcoma, squamous cell carcinoma, or adenocarcinomas
-* T1, grade 3 tumors that were incompletely resected
-* Prostatic duct/acinar CIS
-* Relative indications :
-* Ta or T1 high-grade plus CIS; T1b tumors (ie, deep involvement of lamina propria)
-* Persistent T1, grade 3 tumors identified on reresection
-* Recurrent or persistent disease within 6 to 12 months of initiating treatment with BCG
-* Large-volume Ta, low-grade disease
-* Women with bladder neck and/or urethra CIS
-* However, decisions regarding cystectomy should be individualized based on the surgical risks of the patient.
 *Cystoscopy may be helpful in the diagnosis of transitional cell carcinoma.